You are here

  • Home
  • Archive
  • Volume 19, Issue 6
  • ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus

Article Text

Article menu
Download PDFPDF
Therapeutics
Systematic review with meta-analysis
ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus
  1. Ziv Harel,
  2. Samuel A Silver
  1. St. Michael's Hospital, University of Toronto, USA
  1. Correspondence to : Dr Ziv Harel, St Michael's Hospital, University of Toronto, 61 Queen Street, 7th floor, Toronto, Canada M5C2T2; harelz{at}smh.ca

https://doi.org/10.1136/ebmed-2014-110048

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014;174:773–85.OpenUrlCrossRefPubMedWeb of Science

    Context

    Renin-angiotensin system blockade has been proven to reduce mortality and morbidity in populations at high risk for cardiovascular events. This extends to the patients with diabetes mellitus, where evidence-based guidelines recommend first -line treatment with ACE inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in patients with hypertension and/or proteinuria.1 However, few studies have directly compared ACEIs to ARBs in a randomised-controlled trial (RCT) design. Since ACEIs and ARBs antagonise the renin-angiotensin system through different mechanisms, it is possible that their effects on mortality and cardiovascular outcomes may not be identical.

    Methods

    This was a meta-analysis of RCTs that compared different ACEI and ARB regimens in patients with diabetes …

    View Full Text

    Footnotes

    • Contributors ZH and SAS drafted the manuscript.

    • Competing interests SAS is supported by a Kidney Research Scientist Core Education and National Training Program Post-Doctoral Fellowship.

    • Provenance and peer review Not commissioned; internally peer reviewed.